ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)

被引：2
|
作者：
Ibrahim, Nuhad
Kim, Sung-Bae
Lin, Nancy
Awada, Ahmad
Gil, Eva Ciruelos
Tonini, Giulia
Vallespir, Bartomeu Piza
Theall, Kathy Puvana
Hamilton, Erika
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-05-05
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-05-05
引用
收藏
页数：3
相关论文
共 50 条
  • [1] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Lin, Nancy U.
    Awada, Ahmad
    Gil, Eva Ciruelos
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    CANCER RESEARCH, 2024, 84 (07)
  • [2] ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
    Hamilton, Erika
    Kim, Sung-Bae
    Awada, Ahmad
    Lin, Nancy
    Zuefle, Sebastian
    Scartoni, Simona
    Vallespir, Bartomeu Piza
    Theall, Kathy Puyana
    Ibrahim, Nuhad
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 30 - 31
  • [3] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase 1b/2 study
    Ibrahim, Nuhad K.
    Hamilton, Erika P.
    Kim, Sung-Bae
    Im, Young-Hyuck
    Segui, Elia
    Garcia-Saenz, Jose A.
    Di Sanzo, Alessandro
    Vallespir, Bartomeu Piza
    Lizarbe, Manuel Dominguez
    Wasserman, Tomer
    Theall, Kathy Puyana
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study
    Ciruelos, E. M.
    Hamilton, E. P.
    Kim, S-B.
    Im, Y-H.
    Solis, E. Segui
    Saenz, J. A. Garcia
    Di Sanzo, A.
    Lizarbe, M. Dominguez
    Wasserman, T.
    Theall, K. P.
    Ibrahim, N. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S370 - S370
  • [5] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara
    Loibl, Sibylle
    Tolaney, Sara
    Kaklamani, Virginia
    Tonini, Giulia
    Matheny, Shannon
    Theall, Kathy Puvana
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2024, 84 (09)
  • [6] ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in women and men with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
    Rugo, Hope S.
    Bardia, Aditya
    Cortes, Javier
    Curigliano, Giuseppe
    Hamilton, Erika
    Hurvitz, Sara A.
    Loibl, Sibylle
    Kummel, Sherko
    Scartoni, Simona
    Matheny, Shannon
    Theall, Kathy Puyana
    O'shaughnessy, Joyce
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 32 - 32
  • [7] Elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (adv/mBC): Preliminary data from ELEVATE, a phase 1b/2, open-label, umbrella study
    Rugo, Hope S.
    O'Shaughnessy, Joyce
    Cortes, Javier
    Bardia, Aditya
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Kaklamani, Virginia G.
    Romero, Paula Munoz
    Vallespir, Bartomeu Piza
    Wasserman, Tomer
    Theall, Kathy Puyana
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer
    Hamilton, Erika
    Pusztai, Lajos
    Soliman, Hatem H.
    Hurvitz, Sara
    Grzegorzewski, Krzysztof
    Habboubi, Nassir
    Marreddy, Priya
    Sahmoud, Tarek
    Ibrahim, Nuhad
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study
    Rugo, H. S.
    O'Shaughnessy, J.
    Cortes, J.
    Bardia, A.
    Hamilton, E. P.
    Hurvitz, S. A.
    Kaklamani, V.
    Mchayleh, W.
    Romero, P. Munoz
    Vallespir, B. Piza
    Wasserman, T.
    Theall, K. P.
    Tolaney, S. M.
    ANNALS OF ONCOLOGY, 2024, 35 : S372 - S373
  • [10] A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancer
    Borges, Virginia F.
    Chan, Arlene
    Lin, Nancy U.
    Tonda, Margaret Eleanor
    Shilkrut, Mark
    Alemany, Carlos A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345